Stock Ratings | Leerink Partners initiates coverage of Quince Therapeutics (QNCX) with an "Outperform" rating, setting a price target of $4 with a potential upside of 320%.
Definium Therapeutics, Inc. DFTX | 0.00 | |
Cerebras Systems CBRS | 0.00 | |
Quince Therapeutics, Inc. QNCX | 0.00 | |
Celsius Holdings, Inc. CELH | 0.00 | |
Zeta Global ZETA | 0.00 |
The ratings of major US investment banks are used to track the latest valuations and target prices on Wall Street daily, and to explore potential equity investment opportunities.
Risk warning:
Investing in small-cap stocks can be risky. Be prepared for potential challenges related to liquidity, high volatility, limited information, and financial instability. Always diversify your investments.
Today's key assessments and concerns
Jones Trading: Maintaining a "buy" rating on Definium Therapeutics ( Definium Therapeutics, Inc.(DFTX.US) ), while raising the price target from $61 to $74.
Wedbush: Maintaining Cerebras Systems' Cerebras Systems(CBRS.US) "Outperform Market" rating, while raising its price target from $270 to $280.
Morgan Stanley: Maintaining an "overweight" rating on Cerebras Systems ( Cerebras Systems(CBRS.US) ), while raising the price target from $250 to $273.
Leerink Partners: Initial rating for Quince Therapeutics ( Quince Therapeutics, Inc.(QNCX.US) ) at "outperforms the market", with a price target of $4.
B of A Securities: Maintaining a "buy" rating on Celsius Holdings ( Celsius Holdings, Inc.(CELH.US) ), while lowering the price target from $55 to $45.
| The symbol | Classification | Target price | Current price | Percentage of potential increase/decrease | (Classification) Agency |
| Definium Therapeutics, Inc.(DFTX.US) | to lift | $74.0 | $42.13 | 75.65% | Jones Trading |
| Cerebras Systems(CBRS.US) | to lift | $280.0 | $182.26 | 53.63% | Wedbush |
| Cerebras Systems(CBRS.US) | to lift | $273.0 | $182.26 | 49.79% | Morgan Stanley |
| Zeta Global(ZETA.US) | to lift | $28.0 | $18.84 | 48.62% | B of A Securities |
| Fervo Energy Company Class A(FRVO.US) | to lift | $48.0 | $32.49 | 47.74% | Barclays |
| Quince Therapeutics, Inc.(QNCX.US) | Initial classification | $4.0 | $0.9517 | 320.3% | Leerink Partners |
| Celsius Holdings, Inc.(CELH.US) | cut | $45.0 | $28.52 | 57.78% | B of A Securities |
| Boston Scientific Corporation(BSX.US) | cut | $67.0 | $44.46 | 50.7% | Jefferies |
| Wingstop, Inc.(WING.US) | cut | $234.0 | $155.79 | 50.2% | B of A Securities |
| Celanese Corporation(CE.US) | cut | $68.0 | $48.04 | 41.55% | Citigroup |
comments:
Target price unit and current price: US Dollar;
Current price: As of the latest closing price of US stocks;
Potential percentage increase/potential decrease = (Agency target price - current price) / current price 100% (Current price = Last closing price up to the time of the count)
Lifting
Jefferies: Maintaining a "hold" rating on American Airlines Group American Airlines Group Inc.(AAL.US) stock, while raising the price target from $15 to $16.
BTIG: Maintaining a "Buy" rating on Absci Corporation ( Absci Corporation(ABSI.US) ), while raising the price target from $9 to $13
Morgan Stanley: Maintaining an "overweight" rating on ACM Research ( ACM Research, Inc. Class A(ACMR.US) ), while raising the price target from $90 to $130.
First Coverage
Stifel: Initial rating for BlackBerry ( BlackBerry Limited(BB.US) ) stock at "buy", with a target price of $12.
Citizens: Initial rating for Bitdeer Technologies ( Bitdeer Technologies(BTDR.US) ) at "outperforms the market", with a price target of $35.
Barrington Research: Initial rating for CBIZ ( CBIZ, Inc.(CBZ.US) ) stock at "outperforms the market", with a price target of $45.
reduction
Stifel: Downgraded its rating on Apogee Therapeutics ( Apogee Therapeutics, Inc.(APGE.US) ) to "Hold", while raising its price target from $133 to $135.
Mizuho: Downgraded its rating on Apogee Therapeutics ( Apogee Therapeutics, Inc.(APGE.US) ) to "neutral," while raising its price target from $110 to $135.
Roth Capital: Maintaining a "buy" rating on Anglo Gold ( Anglogold Ashanti PLC(AU.US) ), while lowering the price target from $121 to $110.
Editor's Note: This content was created by Saham's AI-powered SaaS tool and reviewed by our editorial team.
Risk warning:
Investing involves risk, and securities prices can rise or fall, or even become worthless. Investing does not guarantee profits and may result in losses. Past performance is not necessarily indicative of future results. Before making any investment decision, investors should assess their financial situation, investment objectives, experience, and risk tolerance, and understand the nature of the investment products and their associated risks. For more details on the nature and risks of each investment product, please read the relevant offering documents carefully. If you have any questions, it is advisable to seek independent professional advice.